Investors Target Mereo BioPharma Group in Class Action for Alleged Securities Fraud

Investor Alert: Class Action Lawsuit Against Mereo BioPharma Group

Pomerantz LLP has officially filed a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO), sparking attention among investors who have suffered losses from their investment in the biotech firm. This legal action aims to address allegations of securities fraud and other unlawful business practices allegedly committed by Mereo and certain key officers or directors of the company.

The class action invites concerned investors to reach out to Pomerantz LLP for further information. Danielle Peyton is the designated contact person, available for inquiries via email or phone. Investors are encouraged to provide their contact details and information about their shares in Mereo for a more streamlined communication process.

Key Details of the Class Action

Investors have until April 6, 2026, to request the court to appoint them as Lead Plaintiff in this class action, highlighting the urgency of the situation. The lawsuit primarily concerns Mereo’s performance in clinical studies related to its treatments, specifically focusing on two significant studies: the Orbit study and the Cosmic study.

On July 9, 2025, Mereo, in partnership with Ultragenyx Pharmaceutical Inc., announced the progress of the Phase 3 Orbit study involving UX143 (setrusumab) for pediatric and young adult patients suffering from osteogenesis imperfecta (OI). This announcement was followed by a Data Monitoring Committee meeting, which suggested a final analysis would be completed by year-end.

The market reacted sharply to this news; Mereo’s shares saw a decrease of $1.25 per share, translating to a 42.52% drop, a significant hit for many investors.

However, further disappointment awaited investors when, on December 29, 2025, Mereo revealed that neither the Orbit nor Cosmic Phase 3 studies managed to achieve the statistical significance required for their primary endpoints. Despite some improvements in bone mineral density reports, the clinical trials fell short of expectations, leading Mereo’s American Depositary Receipt (ADR) price to plummet an alarming 87.7%, closing at just $0.29 per ADR.

Background and Context

Pomerantz LLP has built a formidable reputation as a leader in corporate, securities, and antitrust class litigation, which dates back 85 years to its founder, Abraham L. Pomerantz. The firm is recognized for its relentless pursuit of justice for shareholders who have faced misconduct in the market.

Many class action lawsuits have collectively recovered significant damages on behalf of investors. As current scenarios unfold with Mereo, investors who believe they have valid claims against the company are urged to act swiftly.

How Investors Can Proceed

Investors wishing to participate in the class action lawsuit should contact Pomerantz LLP promptly. It would be beneficial for investors to prepare their questions and maintain records concerning their share purchases to facilitate the court's review process. The firm advises potential plaintiffs to keep abreast of developments and any updates on significance within the case.

With the clock ticking towards the April deadline, timely action can make a considerable difference for those within the Mereo investment community, whether they’re seeking to reclaim lost investments or hold companies accountable for their actions.

For more details on the lawsuit or to evaluate your standing in this case, reach out to Pomerantz LLP and discuss potential actions you can take as an investor amidst unfolding developments in this high-stakes scenario.